PIPA Conference 2021 – 29th & 30th September
Booking for this year’s PIPA Conference is now open.
Although this will be a virtual event again, we are returning to our traditional 2-day format with joint pharmacovigilance and medical information plenary sessions followed by PV & MI presentations and workshops running in parallel. There will also be dedicated sessions on the ABPI / PAGB Codes and for managers.
1 day: £350 + VAT
2 days: £650 + VAT
PIPA Conference 2021 Programme
Wednesday 29th September
|09:00||Welcome – Tom Nichols, PIPA President|
|09:15||The Art of Brilliance – Dr Andy Cope
This session is absolutely not about challenging you to up your game or work harder, it’s about nudging you to remember who you are at your best. That’s not only good for you. It creates positive ripples that impact on your family, your team and your customers. In a world now dominated by online meetings, THE ART OF BEING BRILLIANT is about unmuting yourself in real life.
The Art of Being Brilliant is based on 20 years of research into positive psychology and the science of human flourishing. The principles are applicable at work and home.
|10:30|| Maternal Health – Current Issues and Possible Solutions – Dr Dave Lewis, Novartis; Belen Granell Villen, ABPI; Amalia Alexe, Novartis
This session will cover three aspects of maternal health: Belen will discuss the work being carried out by the ABPI’s Maternal Health Project Group (MHPG), which was set up to address the issue of a deficit of licensed medicines and treatments designed and researched for use in pregnancy and breastfeeding. Dave will talk about the IMI ConcePTION project which aims to generate and disseminate reliable evidence-based information regarding effects of medications used during pregnancy and breastfeeding to women and their healthcare providers. Finally, Amalia will be discussing the research she has undertaken to analyse, from a patient’s perspective, existing pregnancy exposure safety data to assess the availability of current, credible and comprehensive evidence to inform decisions on benefit-risk.
|11:45||MHRA: Safer Medicines in Pregnancy and Breastfeeding Consortium – Dr Janet Nooney, MHRA
This session will discuss the aims and work being carried out by the Safer Medicines in Pregnancy and Breastfeeding Consortium to improve the consistency of information available to women and their healthcare providers on medicines use during pregnancy and breastfeeding.
|12:15||PIPA AGM 2021|
Track 1: Break Out Sessions
|14:00||A. Workshop: Client Vendor Relationships & SDEA Agreements – Sarah Cox, Cox PharmaConsulting Ltd.
The workshop will cover Safety Data Exchange Agreements (SDEA) and their lifecycle management. It will also consider the distribution of responsibilities between a marketing authorisation holder and a pharmacovigilance provider and then with those third parties requiring an SDEA.
B. Workshop: ABPI & PAGB Code of Practice – Laura Kelly, PAGB; Dan Sherry, RedefineCompliance; Wendy Lloyd-Goodwin, Life Science Law
The session will be looking at the principles underlying the ABPI and PAGB Codes, including best practice advice on copy approvals and recent developments in digital and social media. Using examples we’ll outline the differences between promoting a POM and OTC product, and the pros and cons when considering reclassification.
|15:45||Break out sessions continued|
TRACK 2: Managers’ Workstream
|14:00||Agile Workshop for Life Science Professionals – Will Sillar, Insight Partner; Rachelle Furnell, Agile SME; Michael Tedeschi, Agile and Life Science SME; Olivia Morris-Barry, Lead Facilitator
Say goodbye to siloed working, process for process sake, and old-style big bang delivery. In this session we will welcome you to an Agile team, the frameworks and the modern implications of Agile in the life science industry. You will receive a demonstration of how Agile teams work and practical experience of a scrum master. You will walk away with insight on how to move towards an Agile working environment in your team.
Thursday 30th September
|09:00||Ageing healthily: a challenge for the 21st century? – Dr James Brown, Director of Aston Research Centre for Healthy Ageing (ARCHA)|
|10:00||Time to embrace the inevitable reality of human performance in complex systems – Brian Edwards, Chartered Institute of Ergonomics and Human Factors; Helen Hughes, Patient Safety Learning
The professional body for Human Factors and Ergonomics within the UK – the Pharmaceutical Human Factors Special Interest Group (SIG) – was formed in 2015. In this session, we will discuss:
TRACK 1: Medical Information
|11:15||Chatbot and Conversational AI Case Studies – Shailini Blackwell, ConversationHealth & Julie Boothe, Orion Pharma; Justin Mardjuki, Lifelink Systems
Case Study (Conversation Health): From strategic vision to kick off – lessons learned in delivering Orion’s first Med Info conversational AI agent: Orion Pharma has set out to transform the provision of Medical Information services to HCPs and patients – looking to leverage conversational AI as a key channel for digital engagement that meets – and surpasses – the needs of their customers.
Lifelink Systems: Conversational AI is changing the way consumers interact with healthcare providers and life science companies. Lifelink Systems is automating more than 10 million automated, digital interactions with patients and trial participants each year. In this session, we will review several customer case studies to show participants how the technology works, the engagement results, and the ROI our customers are seeing.
|12:15||Global MI – one size doesn’t fit all – Sarah Hall, Mipsol Ltd
This presentation will cover the different structures of Medical Information departments (in-house, outsourced or a mixture of the two) highlighting the pros and cons and things to consider.
TRACK 2: Pharmacovigilance
|11:15||Medical Device Regulations– Rob Higgins, Senior Regulatory Affairs Manager, MHRA
In this session, the MHRA will present on the UK device requirements including key considerations manufacturers should be aware of, what inspectors look for during inspections, the common findings seen and any oversights that have been noted. Also, they will highlight how the UK requirements differ from the EU MDR and IVDR.
|12:15||MHRA Inspections – what are they looking for? – Raj Bhogal, Jazz Pharma
In this session, Raj will discuss the following:
Break Out Sessions
|14:00||A. Workshop: COVID-19 and Pharmacovigilance – lessons learned so far – Tom Nichols, DrivePhase PV
This interactive workshop will discuss:
– how existing treatments have been repurposed and evaluated as treatments for COVID-19
– putting in place a pharmacovigilance system for the vaccine
B. Workshop: Pharma and the NHS – the relationship that needs to take the next step? – Harpreet Sandhu, Grunenthal & Alan Ryan, Director of National Programmes for Health Education England
With guest speakers from the NHS and Pharma, this workshop will explore the extra step the pharmaceutical industry can take to ensure timely provision of essential information – and potentially training – to healthcare professionals to facilitate the best patient experience.
|15:45||Break out sessions continued|